Tempest Therapeutics Inc (TPST) Stock Price, Quote & News

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 798 8589

Website: www.tempesttx.com

Address:

2000 Sierra Point Parkway, Suite 400, Brisbane, United States

Xamayca Aug. 19 at 10:09 AM

$TPST Recession incoming BP sitting on piles of cash deal making time is now, might not be as sexy as we’d imagined but if it’s coming anytime it’s in the next 0-90 days mark my words

0 · Reply

Bullish_Parantaman Aug. 19 at 7:54 AM

$KIDZ $PFSA $TPST $CAST

0 · Reply

joeyknowie Aug. 19 at 7:10 AM

$TPST folks this has been fun but I’m signing off of this platform. I reduced my shares to 100k today down from 125k shares bc I don’t t love the impending dilution risk and very low cash. I do like the potential and so I keep 100k shares which is the same as about $100,000 as of right now. BEST of luck @Xamayca and all the other longs. I’m leaving here because I want to distance from the day to day stress and ins and outs and if I lose what I have invested so be it. In time we will see if I’m a fool or not but I won’t sell from here until the end game. Best of luck to all stakeholders. @joeyknowie out. Much love.

3 · Reply

joeyknowie Aug. 19 at 4:39 AM

$TPST serious question — is Amezalpat dead in the water? Yes it had good clinical trial results in conjunction with Roche’s tecentric but it seems like Roche’s subsidiary Genentech’s drug had a better survival rate. Amezalpat is a pill versus an IV administered drug so there’s that and it’s not nothing but…where it is is at a place where there is a turn key phase 3 study widely approved but anyone who wants to take it on is committing to an at least $100 million investment that won’t necessarily produce good results. So…is it a pipe dream that it will ever be sold? If it is to be sold imo it is most likely in the Asian market so the pivot that direction makes some sense …but even in Asian market where liver cancer is much more prevalent is there a business proposition that actually makes it worthwhile for someone to acquire Amezalpat with the built in massive cost for the trial that comes with risk? Could it just die on the vine given the cost and risk despite great clinical?

1 · Reply

Bullish_Parantaman Aug. 19 at 3:28 AM

$KIDZ $PFSA $TPST $CAST

0 · Reply

joeyknowie Aug. 18 at 11:56 PM

$TPST short of a legacy asset sale or license deal they need a pipeline catalyst to drive the price to a range where those Sabby $1.73 warrants come into play.

0 · Reply

The_Titan_Traders Aug. 18 at 11:37 PM

$CAST $KIDZ $PFSA $TPST $KIDZ trying to breakout again

2 · Reply

johnrivers0110 Aug. 18 at 10:45 PM

$TPST 🔺🩸🔪🔪🔪🔪🔪

0 · Reply

The_Titan_Traders Aug. 18 at 10:44 PM

$KIDZ 300k float, similarities between this and $PFSA $TPST $CAST are pretty striking.

0 · Reply

Xamayca Aug. 18 at 10:01 PM

$TPST Too much action going on around financing etc for negotiations not to be happening behind the scenes. We didn’t obtain 50m line in the hopes of attracting a fish 🐟 there must be one on the hook already now we are showing we have the line to land him

1 · Reply

Tempest Therapeutics Proxy statement: Proxy filing

Aug 13, 2026, 4:25 PM EDT - 5 days ago

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 13, 2026, 4:00 PM EDT - 5 days ago

Tempest Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 5 days ago

Tempest Therapeutics Quarterly report: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 21 days ago

Tempest Therapeutics Proxy statement: Proxy filing

Jul 21, 2026, 7:00 AM EDT - 4 weeks ago

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Jul 17, 2026, 8:00 AM EDT - 4 weeks ago

Tempest Therapeutics Proxy statement: Proxy filing

Jul 15, 2026, 8:00 AM EDT - 4 weeks ago

Tempest Therapeutics Slides: Corporate presentation

Jul 15, 2026, 7:00 AM EDT - 5 weeks ago

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Jul 7, 2026, 8:00 AM EDT - 6 weeks ago

Tempest Therapeutics Proxy statement: Proxy filing

2026-06-26T20:10:33.000Z - 7 weeks ago

Tempest Therapeutics registers to sell 2.43M shares of common stock for holders

Jun 26, 2026, 8:00 AM EDT - 7 weeks ago

Tempest Therapeutics Registration statement: Registration filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Proxy statement: Proxy filing

Jun 4, 2026, 4:37 PM EDT - 2 months ago

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

May 29, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Proxy statement: Proxy filing

May 14, 2026, 4:15 PM EDT - 3 months ago

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:00 PM EDT - 3 months ago

Tempest Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Tempest Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 3 months ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 3 months ago

Tempest Therapeutics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

2026-04-22T12:30:21.000Z - 4 months ago

Tempest Therapeutics provides update on development of TPST-2003

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Tempest Therapeutics Registration statement: Registration filing

2026-04-02T10:11:28.000Z - 4 months ago

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

2026-03-30T22:05:33.000Z - 5 months ago

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

Mar 30, 2026, 9:00 AM EDT - 5 months ago

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 8:30 AM EDT - 5 months ago

Tempest Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 5 months ago

Tempest Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Tempest Therapeutics Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Tempest Therapeutics Announces Up To $6 Million Private Placement

2026-03-11T12:06:24.000Z - 5 months ago

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

Mar 11, 2026, 8:00 AM EDT - 5 months ago

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

2026-02-25T13:24:11.000Z - 6 months ago

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

Feb 25, 2026, 7:59 AM EST - 6 months ago

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Feb 11, 2026, 6:59 AM EST - 6 months ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 6 months ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

2026-01-22T11:12:02.000Z - 7 months ago

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Jan 20, 2026, 5:20 PM EST - 7 months ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Dec 31, 2025, 7:00 AM EST - 8 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

2025-12-09T21:55:14.000Z - 9 months ago

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

Dec 9, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Registration statement: Registration Filing

Dec 2, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Nov 26, 2025, 4:05 PM EST - 9 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

2025-11-25T13:05:18.000Z - 9 months ago

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

Nov 25, 2025, 8:00 AM EST - 9 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

2025-11-19T14:11:00.000Z - 9 months ago

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

Nov 19, 2025, 9:00 AM EST - 9 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Nov 19, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Nov 5, 2025, 9:00 AM EST - 10 months ago

Tempest Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 10 months ago

Tempest Therapeutics Earnings release: Q3 2025

2025-11-05T13:36:56.000Z - 10 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

Nov 5, 2025, 8:30 AM EST - 10 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-08-11T20:55:19.000Z - 1 year ago

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

Aug 11, 2025, 4:12 PM EDT - 1 year ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q2 2025

2025-06-30T14:37:56.000Z - 1 year ago

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

2025-06-11T12:20:36.000Z - 1 year ago

Tempest prices 739,000 shares at $6.25 in registered direct offering

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

2025-06-05T12:05:21.000Z - 1 year ago

Tempest Therapeutics receives ODD from EMA for amezalpat

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

2025-05-13T20:35:15.000Z - 1 year ago

Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)

May 13, 2025, 4:28 PM EDT - 1 year ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q1 2025

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 9, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Slides: Corporate Presentation

Mar 27, 2025, 4:10 PM EDT - 1 year ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 24, 2025, 7:00 AM EST - 1 year ago

Tempest Therapeutics Registration statement: Registration Filing

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Dec 3, 2024, 9:00 AM EST - 1 year ago

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing

Oct 10, 2024, 7:01 AM EDT - 2 years ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Sep 20, 2024, 4:30 PM EDT - 2 years ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:00 AM EDT - 2 years ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 8, 2024, 4:56 PM EDT - 2 years ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q2 2024

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Registration statement: Registration Filing

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Slides: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Press release: Study Update

Jun 18, 2024, 6:22 PM EDT - 2 years ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 5, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

May 29, 2024, 2:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 9, 2024, 4:29 PM EDT - 2 years ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q1 2024

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Annual report: Q4 2023

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 4, 2024, 9:10 AM EST - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Nov 28, 2023, 3:00 PM EST - 2 years ago

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Xamayca Aug. 19 at 10:09 AM

$TPST Recession incoming BP sitting on piles of cash deal making time is now, might not be as sexy as we’d imagined but if it’s coming anytime it’s in the next 0-90 days mark my words

0 · Reply

Bullish_Parantaman Aug. 19 at 7:54 AM

$KIDZ $PFSA $TPST $CAST

0 · Reply

joeyknowie Aug. 19 at 7:10 AM

3 · Reply

joeyknowie Aug. 19 at 4:39 AM

1 · Reply

Bullish_Parantaman Aug. 19 at 3:28 AM

$KIDZ $PFSA $TPST $CAST

0 · Reply

joeyknowie Aug. 18 at 11:56 PM

$TPST short of a legacy asset sale or license deal they need a pipeline catalyst to drive the price to a range where those Sabby $1.73 warrants come into play.

0 · Reply

The_Titan_Traders Aug. 18 at 11:37 PM

$CAST $KIDZ $PFSA $TPST $KIDZ trying to breakout again

2 · Reply

johnrivers0110 Aug. 18 at 10:45 PM

$TPST 🔺🩸🔪🔪🔪🔪🔪

0 · Reply

The_Titan_Traders Aug. 18 at 10:44 PM

$KIDZ 300k float, similarities between this and $PFSA $TPST $CAST are pretty striking.

0 · Reply

Xamayca Aug. 18 at 10:01 PM

1 · Reply

Xamayca Aug. 18 at 9:34 PM

$TPST Even a simple announcement about Morpheus updates due at ESMO and the data embargo lifting on October 19th would go along way (a legal hint) of some sort

0 · Reply

frankPF Aug. 18 at 9:20 PM

$TPST Wenn Morpheus schlecht ist → TPST ist tot. Wenn Morpheus gut ist → TPST lebt. Es gibt keinen Plan B.

2 · Reply

frankPF Aug. 18 at 9:05 PM

$TPST sie müssen liefer,JETZT,sonst können sie den Septembertermin gleich heute streichen🤢

1 · Reply

TwongStocks Aug. 18 at 8:30 PM

$TPST No changes have been made to the Proposal to be voted on by the stockholders at the Special Meeting. The record date for determining stockholder eligibility to vote at the Special Meeting remains the close of business on May 28, 2026.

1 · Reply

TwongStocks Aug. 18 at 8:30 PM

$TPST 8-K filed. Confirms the meeting adjournment to Sept 15 at 12:00pm ET. https://www.sec.gov/ix?doc=/Archives/edgar/data/1544227/000119312526355550/d919907d8k.htm At the Special Meeting, a total of 10,601,849 shares, or 71.6% of the 14,806,997 shares of common stock outstanding as of May 28, 2026, the record date for the Special Meeting, were present virtually or represented by proxy, constituting a quorum. However, because there were not sufficient votes to approve the Proposal at the time of the Special Meeting, the Company decided to adjourn the Special Meeting to provide stockholders with additional time to vote and to facilitate broader participation.

0 · Reply

lousjamsession Aug. 18 at 5:09 PM

$TPST Tempest is playing a classic biotech playbook: securing survival runway while cleaning up corporate mechanics so they can move fast on pipeline catalysts. The $50 million Lincoln Park deal serves as an on-demand cash tap to fund clinical trials without resorting to predatory high-discount offerings, even though every draw gradually expands the float and dilutes current shares. At the same time, management is pushing hard to clear the 75% shareholder vote to allow written consent actions, removing the delay and massive expense of holding formal special meetings whenever they need to pivot or raise capital. the Lincoln Park backstop gives Tempest the financial runway to push its lead in vivo CAR-T candidate, TPST-4003, into first-in-human clinical dosing by Q4 2026.

2 · Reply

Xamayca Aug. 18 at 11:36 AM

$TPST I meant to da they will announce the vote xld within the next t couple of days and keep the September 15 vote with a brand new record date where date where they control well over the 75percent needed

1 · Reply

Xamayca Aug. 18 at 9:10 AM

$TPST I have researched they actually have painted themselves into a corner they can’t really effectively use the Lincoln Capital funds without the vote because they are capped at19.99 percent of the stock less than 3million shares and many who owned shares on May28th record date have dumped and no doubt more will now that they have failed again what idiots we have in charge. Who amongst us would answer a call from a telemarketer to vote on a stock we sold at a loss anytime in the last 90 days. I pray they find a way out of this one!

1 · Reply

Sauhaufen Aug. 18 at 8:42 AM

$TPST Is there a buyout coming to us? 🤔🤨🧐

0 · Reply

HectorNumba9 Aug. 18 at 7:41 AM

$TPST We caved for 25% profit im sorry i wont do it for the 3rd time 😂its not funny

0 · Reply

HectorNumba9 Aug. 18 at 7:39 AM

$TPST Bulls needed $$ im sorry trust me 😂

0 · Reply

Michl2000 Aug. 18 at 5:51 AM

$TPST bullish or bullshit ???

1 · Reply

Market Cap	18.06M
Revenue (ttm)	0.00
Net Income (ttm)	-26.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	334,800
Avg Vol	230,698
Day's Range	N/A - N/A
Shares Out	15.98M
Stochastic %K	47%
Beta	-1.72
Analysts	Sell
Price Target	$11.00